SERA icon

Sera Prognostics

4.12 USD
-0.15
3.51%
At close Feb 21, 4:00 PM EST
1 day
-3.51%
5 days
-3.06%
1 month
-37.95%
3 months
-32.57%
6 months
-42.78%
Year to date
-50.54%
1 year
-56.45%
5 years
-65.38%
10 years
-65.38%
 

About: Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.

Employees: 57

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

18% more funds holding

Funds holding: 61 [Q3] → 72 (+11) [Q4]

4% less capital invested

Capital invested by funds: $147M [Q3] → $141M (-$6.06M) [Q4]

5.35% less ownership

Funds ownership: 58.26% [Q3] → 52.91% (-5.35%) [Q4]

35% less call options, than puts

Call options by funds: $235K | Put options by funds: $361K

Research analyst outlook

We haven’t received any recent analyst ratings for SERA.

Financial journalist opinion

Based on 4 articles about SERA published over the past 30 days

Neutral
PRNewsWire
23 hours ago
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference
SALT LAKE CITY , Feb. 21, 2025 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m.
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference
Neutral
PRNewsWire
1 week ago
Sera Prognostics Announces Pricing of $50 Million Public Offering
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which equals the public offering price per share of the Class A common stock less the $0.0001 per share exercise price of each pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sera, are expected to be approximately $50 million.
Sera Prognostics Announces Pricing of $50 Million Public Offering
Neutral
PRNewsWire
1 week ago
Sera Prognostics Announces Proposed Public Offering
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock.  In addition, Sera intends to grant the underwriters a 30-day option to purchase shares of Class A common stock in an amount up to an additional 15% of the total amount of shares of Class A common stock and shares of Class A common stock underlying pre-funded warrants sold in the public offering on the same terms and conditions.
Sera Prognostics Announces Proposed Public Offering
Neutral
PRNewsWire
3 weeks ago
Sera Prognostics to Host Virtual R&D Day on January 31
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY , Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m.
Sera Prognostics to Host Virtual R&D Day on January 31
Neutral
PRNewsWire
1 month ago
Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY , Jan. 6, 2025 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco.
Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Neutral
PRNewsWire
2 months ago
Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
SALT LAKE CITY , Dec. 4, 2024 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting™ on January 31, 2025 at 10:15 a.m. MT . Dr. Brian Iriye – maternal-fetal medicine expert at the High Risk Pregnancy Center in Las Vegas, Nevada, and principal investigator for the PRIME study – will present the results of the full PRIME study.
Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
Neutral
PRNewsWire
2 months ago
Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference
SALT LAKE CITY , Dec. 2, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 2:30 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.
Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference
Neutral
PRNewsWire
3 months ago
Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SALT LAKE CITY , Nov. 15, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.
Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Neutral
Seeking Alpha
3 months ago
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript
Sera Prognostics Inc (NASDAQ:SERA ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Peter DeNardo - IR Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes.
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago.
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
Charts implemented using Lightweight Charts™